Improved corneal toxicity and permeability of tranilast by the preparation of ophthalmic formulations containing its nanoparticles

Journal of Oleo Science

Volumn 63, Issue 2, 2014, Pages 177-186

  Nagai, Noriaki ^a   Ono, Hikaru ^a   Hashino, Miho ^a   Ito, Yoshimasa ^a   Okamoto, Norio ^b   Shimomura, Yoshikazu ^b  

^a KINKI UNIVERSITY   (Japan)

^b NONE   (Japan)

Author keywords

Corneal stimulation; Eye drops; Nanoparticle; Tranilast; Transcorneal penetration

Indexed keywords

ANTI-MICROBIAL ACTIVITY; BENZALKONIUM CHLORIDE; CORNEAL STIMULATION; DRUG NANO PARTICLES; EYE DROPS; OCULAR DRUG DELIVERY SYSTEMS; TRANILAST; TRANSCORNEAL;

CHLORINE COMPOUNDS; DISPERSIONS; DROPS; DRUG DELIVERY; ESCHERICHIA COLI; TOXICITY; ZIRCONIA;

NANOPARTICLES;

ANTHRANILIC ACID DERIVATIVE; EYE DROPS; NANOPARTICLE; TRANILAST; ZIRCONIUM; ZIRCONIUM OXIDE;

ANIMAL; ANTIBIOTIC RESISTANCE; ARTICLE; CELL LINE; CORNEA; DRUG DELIVERY SYSTEM; DRUG EFFECT; EPITHELIUM CELL; ESCHERICHIA COLI; HUMAN; MALE; MEDICINAL CHEMISTRY; METABOLISM; RABBIT;

ANIMALS; CELL LINE; CHEMISTRY, PHARMACEUTICAL; CORNEA; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, BACTERIAL; EPITHELIAL CELLS; ESCHERICHIA COLI; HUMANS; MALE; NANOPARTICLES; OPHTHALMIC SOLUTIONS; ORTHO-AMINOBENZOATES; RABBITS; ZIRCONIUM;

EID: 84893337342     PISSN: 13458957     EISSN: 13473352     Source Type: Journal    
DOI: 10.5650/jos.ess13082     Document Type: Article

References (41)

1. Diebold, Y.; Jarrin, M.; Saez, V.; Carvalho, E. L. S.; Orea, M.; Calonge, M.; Seijo, B.; Alonso, M. J. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials 28, 1553-1564 (2007).
2. Baba, K.; Tanaka, Y.; Kubota, A.; Kasai, H.; Yokokura, S. Nakanishi, H.; Nishida, K. A method for enhancing the ocular penetration of eye drops using nanoparticles of hydrolysable dye. J. Control. Release 153, 278-287 (2011).
3. Li, X.; Zhang, Z.; Li, J.; Sun, S.; Weng, Y; Chen, H. Di-clofenac/biodegradable polymer micelles for ocular applications. Nanoscale 4, 4667-4673 (2012).
4. Asasutjarit, R.; Thanasanchokpibull, S.; Fuongfuchat, A.; Veeranodha, S. Optimization and evaluation of thermoresponsive diclofenac sodium ophthalmic in situ gels. Int. J. Pharm. 411, 128-135 (2011).
5. Mahmoud, A. A.; El-Feky, G. S.; Kamel, R.; Awad, G. E. A. Chitosan/sulfobutylether-[beta]-cyclodextrin nanoparticles as a potential approach for ocular drug delivery. Int. J. Pharm. 413, 229-236 (2011).
6. Ammar, H. O.; Salama, H. A.; Ghorab, M.; Mahmoud, A. A. Nanoemulsions as potential ophthalmic delivery systems for orzolamide hydrochloride. AAPS Pharm. Sci. Tech. 10, 808-819 (2009).
7. El-Kamel, A. H. In vitro and in vivo evaluation of Plu-ronic F127-based ocular delivery system for timolol maleate. Int. J. Pharm. 241, 47-55 (2002).
8. Sultana, Y.; Aqil, M.; Ali, A. Ion-activated, Gelrite-based in situ ophthalmic gels of pefloxacin mesylate: comparison with conventional eye drops. Drug Deliv. 13, 215-219 (2006).
9. Gupta, H.; Aqil, M.; Khar, R. K.; Ali, A.; Bhatnagar, A.; Mittal, G. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. J. Drug Target. 19, 409-417 (2011).
10. Casolaro, M.; Casolaro, I.; Lamponi, S. Stimuli-responsive hydrogels for controlled pilocarpine ocular delivery. Eur J. Pharm. Biopharm. 80, 553-561 (2012).
11. Davies, N. M.; Fair, S. J.; Hadgraft, J.; Kellaway, I. W. Evaluation of mucoadhesive polymers in ocular drug delivery. I. Viscous solutions. J. Pharm. Sci. 8, 1039-1043 (1991).
12. Rafie, F.; Javadzadeh, Y.; Javadzadeh, A. R.; Ghavidel, L. A.; Jafari, B., Moogooee, M., Davaran, S. In vivo evaluation of novel nanoparticles containing dexa-metha-sone for ocular drug delivery on rabbit eye. Curr Eye Res. 35, 1081-1089 (2010).
13. Cohen, S.; Yoshioka, T.; Lucarelli, M.; Hwang, L. H.: Langer, R. Controlled delivery systems for proteins based on poly (lactic/glycolic acid)microspheres. Pharm. Res. 8, 713-720 (1991).
14. Tomoda, K.; Watanabe, A.; Suzuki, K.; Inagi, T.; Terada, H.; Makino, K. Enhanced transdermal permeability of estradiol using combination of PLGA nanoparticles system and iontophoresis. Colloids Surf. B Biointer faces, 97, 84-89 (2012).
15. Tomoda, K.; Terashima, H.; Suzuki, K.; Inagi, T.; Terada, H.; Makino, K. Enhanced transdermal delivery of indomethacin using combination of PLGA nanoparticles and iontophoresis in vivo. Colloids Surf. B Bio-interfaces, 92, 50-54 (2012).
16. Tomoda, K.; Terashima, H.; Suzuki, K.; Inagi, T; Terada, H.; Makino, K. Enhanced transdermal delivery of indomethacin-loaded PLGA nanoparticles by iontophoresis. Colloids Surf B Biointerfaces, 88, 706-710 (2011).
17. Pfab, T.; Hocher, B. Tranilast and hypertensive heart disease: further insights into mechanisms of an anti-inflammatory and anti-fibrotic drug. J. Hypertens., 22, 883-886 (2004).
18. Suzawa, H.; Kikuchi, S.; Ichikawa, K.; Koda, A. Inhibitory action of tranilast, an anti-allergic drug, on the release of cytokines and PGE2 from human monocytes-macrophages. Jpn. J. Pharmacol, 60, 85-90 (1992).
19. Shimizu, T; Kanai, K.; Kyo, Y; Asano, K.; Hisamitsu, T: Suzaki, H. Effect of tranilast on matrix metalloprotein-ase production from neutrophils in-vitro. J. Pharm. Pharmacol. 58, 91-99 (2006).
20. Kagitani, S.; Ueno, H.; Hirade, S.; Takahashi, T; Taka-ta, M.; Inoue, H. Tranilast attenuates myocardial fibro-sis in association with suppression of monocyte/mac-rophage infiltration in DOCA/salt hypertensive rats. J. Hypertens. 22, 1007-1015 (2004).
21. Pisella, P. J.; Fillacier, K.; Elena, P. P.; Debbasch, C, Baudouin, C. Comparison of the effects of preserved and unpreserved formulations of timolol on the ocular surface of albino rabbits. Ophthalmic. Res. 32, 3-8 (2000).
22. Nagai, N.; Murao, T; Oe, K.; Ito, Y; Okamoto, N.; Shi-momura, Y In vitro evaluation for corneal damages by anti-glaucoma combination eye drops using human corneal epithelial cell (HCE-T). Yakugaku Zasshi 131, 985-991 (2011).
23. Yakuji Nippo Ltd. Japanese Pharmacopoeia. Tokyo. Maruzen Co., Ltd, 15 (2006).
24. Araki-Sasaki, K.; Ohashi, Y; Sasabe, T; Hayashi, K., Watanabe, H.; Tano, Y; Handa, H. An SV40-immortal-ized human corneal epithelial cell line and its characterization. Invest. Ophthalmol. Vis. Sci, 36, 614-621 (1995).
25. Nagai, N.; Ito, Y; Okamoto, N.; Shimomura, Y Decrease in corneal damage due to benzalkonium chloride by the addition of sericin into timolol maleate eye drops. J. Oleo Sci. 62, 159-166 (2013).
26. Iwata, S.; Osada, Y; Ogino, H. Aspect on corneal permeability of bupranolol. YAKUGAKU ZASSI 100, 402-406 (1980).
27. Rolando, M.; Brezzo, G.; Giordano, P.; Campagna, P, Burlando, S.; Calabria, G. The Lacrimal System, ed. by Van, Bijsterweld, O. P.; Lemp, M. A.; Spinelli, D. Ka-gler & Ghedini, Amsterdam, pp. 89-91 (1991).
28. Debbasch, C; Pisella, P. J.; De, Saint, Jean, M.; Rat, P, Warnet, J. M.; Baudouin, C. Mitochondrial activity and glutathione injury in apoptosis induced by unpreserved and preserved beta-blockers on Chang con-junctival cells. Invest. Ophthalmol. Vis. Sci. 42, 2525-2533 (2001).
29. Wilson, W. S.; Duncan, A. J.; Jay, J. L. Effect of benzalkonium chloride on the stability of the precorneal tear film in rabbit and man. Br J. Ophthalmol. 59, 667-669 (1975).
30. Kuppens, E. V; de Jong, C. A.; Stolwijk, T. R.; De Keizer, R. J.; Van, Best, J. A. Effect of timolol with and without preservative on the basal tear turnover in glaucoma. Br. J. Ophthalmol. 79, 339-342 (1995).
31. Burstein, N. L. Preservative cytotoxic threshold for benzalkonium chloride and chlorhexidine digluconate in cat and rabbit corneas. Invest. Ophthalmol. Vis. Sci. 19, 308-313 (1980).
32. De, Saint, Jean, M.; Debbasch, C; Brignole, F; Rat, P, Warnet, J. M.; Baudouin, C. Toxicity of preserved and unpreserved antiglaucoma topical drugs in an in vitro model of conjunctival cells. Curr. Eye Res. 20, 85-94 (2000).
33. De, Saint, Jean, M.; Brignole, F; Bringuier, A. F Effects of benzalkonium chloride on growth and survival of Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 40, 619-630 (1999).
34. Guenoun, J. M.; Baudouin, C; Rat P.; Pauly, A.; Warnet, J. M.; Briqnole, Baudouin F In vitro study of inflammatory potential and toxicity profile travoprost, and bimatoprost in conjunctiva-derived epithelial cells. Invest. Ophthalmol. Vis. Sci. 46, 2444-2450 (2005).
35. Guenoun, J. M.; Baudouin, C; Rat, P.; Pauly, A.; Bri-qnole-Baudouin, F. In vitro comparison of cytoprotec-tive and antioxidative effects of latanoprost, travoprost, and bimatoprost on conjunctiva-derived epithelial cells. Invest. Ophthalmol. Vis. Sci. 46, 4594-4599 (2005).
36. Debbasch, C; Brignole, F.; Pisella, P. J.; Warnet, J. M., Rat, P.; Baudouin, C. Quaternary ammoniums and other preservatives' contribution in oxidative stress and apoptosis on Chang conjunctival cells. Invest. Ophthalmol. Vis. Sci. 42, 642-652 (2001).
37. Chung, S. H.; Lee, S. K.; Cristol, S. M.; Lee, D. W.; Seo, K. Y.; Kim, E. K. Impact of short-term exposure of commercial eyedrops preserved with benzalkonium chloride on precorneal mucin. Mol. Vis. 12, 415-421 (2006).
38. Mori, K.; Yoshioka, N.; Kondo, Y; Takeuchi, T.; Ya-mashita, H. Catalytically Active, Magnetically Separable, and Water-soluble FePt Nanoparticles Modified with Cyclodextrin for Aqueous Hydrogenation Reactions. Green Chem. 11, 1337-1342 (2009).
39. Okamoto, N.; Ito, Y; Nagai, N.; Murao, T.; Takiguchi, Y, Kurimoto, T.; Mimura, O. Preparation of ophthalmic formulations containing cilostazol as an anti-glaucoma agent and improvement in its permeability through the rabbit cornea. J. Oleo Sci. 59, 423-430 (2010).
40. Jansen, T.; Xhonneux, B.; Mesens, J.; Borgers, M. Beta-cyclodextrins as vehicles in eye-drop formulations: an evaluation of their effects on rabbit corneal epithelium. Lens Eye Toxic. Res. 7, 459-468 (1990).
41. Kawabata, Y; Yamamoto, K.; Debari, K.; Onoue, S.; Ya-mada, S. Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavail-ability. Eur J. Pharm. Sci. 39, 256-262 (2010).